These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1270 related items for PubMed ID: 22335009

  • 1. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P, Zwolińska-Wcisło M, Przybylska M, Mach T.
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F, Giudici F, Asteria CR.
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [Abstract] [Full Text] [Related]

  • 3. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of combined anti-TNF-alpha and surgical therapy in perianal and enterocutaneous fistulizing Crohn's disease--clinical observations from a tertiary Eastern European center.
    Bor R, Farkas K, Bálint A, Szucs M, Ábrahám S, Baradnay G, Wittmann T, Szepes Z, Nagy F, Molnár T.
    Scand J Gastroenterol; 2015 Feb; 50(2):182-7. PubMed ID: 25384713
    [Abstract] [Full Text] [Related]

  • 5. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
    Ng SC, Plamondon S, Gupta A, Burling D, Swatton A, Vaizey CJ, Kamm MA.
    Am J Gastroenterol; 2009 Dec; 104(12):2973-86. PubMed ID: 19755971
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L.
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [Abstract] [Full Text] [Related]

  • 7. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

  • 8. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID.
    Amiot A, Setakhr V, Seksik P, Allez M, Treton X, De Vos M, Laharie D, Colombel JF, Abitbol V, Reimund JM, Moreau J, Veyrac M, Flourié B, Cosnes J, Lemann M, Bouhnik Y.
    Am J Gastroenterol; 2014 Sep 01; 109(9):1443-9. PubMed ID: 25091063
    [Abstract] [Full Text] [Related]

  • 10. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M.
    Scand J Gastroenterol; 2013 May 01; 48(5):543-51. PubMed ID: 23477356
    [Abstract] [Full Text] [Related]

  • 11. Review article: Medical therapy for fistulizing Crohn's disease.
    Bressler B, Sands BE.
    Aliment Pharmacol Ther; 2006 Nov 01; 24(9):1283-93. PubMed ID: 17059510
    [Abstract] [Full Text] [Related]

  • 12. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
    Ochsenkühn T, Göke B, Sackmann M.
    Am J Gastroenterol; 2002 Aug 01; 97(8):2022-5. PubMed ID: 12190171
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
    Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA, Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis.
    Aliment Pharmacol Ther; 2007 Feb 15; 25(4):409-18. PubMed ID: 17269996
    [Abstract] [Full Text] [Related]

  • 14. Infliximab in fistulizing Crohn's disease.
    Osterman MT, Lichtenstein GR.
    Gastroenterol Clin North Am; 2006 Dec 15; 35(4):795-820. PubMed ID: 17129814
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcome of Crohn's disease treated with infliximab.
    Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tözün N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dökmeci A.
    Hepatogastroenterology; 2003 Dec 15; 50(52):952-6. PubMed ID: 12845957
    [Abstract] [Full Text] [Related]

  • 16. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM, Krauss N, Voll RE, Nägel A, Weidenhiller M, Konturek PC, Hahn EG, Raithel M.
    Digestion; 2008 Dec 15; 78(4):195-200. PubMed ID: 19122456
    [Abstract] [Full Text] [Related]

  • 17. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas.
    Ng SC, Plamondon S, Gupta A, Burling D, Kamm MA.
    Aliment Pharmacol Ther; 2009 Oct 15; 30(7):757-66. PubMed ID: 19575762
    [Abstract] [Full Text] [Related]

  • 18. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301
    [Abstract] [Full Text] [Related]

  • 19. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ.
    N Engl J Med; 1999 May 06; 340(18):1398-405. PubMed ID: 10228190
    [Abstract] [Full Text] [Related]

  • 20. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P, Ng SC, Siddiqui MR, Plamondon S, Burling D, Gupta A, Swatton A, Tripoli S, Vaizey CJ, Kamm MA, Phillips R, Hart A.
    Inflamm Bowel Dis; 2012 Oct 06; 18(10):1825-34. PubMed ID: 22223472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.